Tumor Receptor-Mediated In Vivo Modulation of the Morphology, Phototherapeutic Properties, and Pharmacokinetics of Smart Nanomaterials
Citations Over TimeTop 16% of 2020 papers
Abstract
To be clinically efficacious, nanotherapeutic drugs need to reach disease tissues reliably and cause limited side effects to normal organs and tissues. Here, we report a proof-of-concept study on the development of a smart peptidic nanophototherapeutic agent in line with clinical requirements, which can transform its morphology from nanoparticles to nanofibrils at the tumor sites. This in vivo receptor-mediated transformation process resulted in the formation and prolonged tumor-retention of highly ordered (J-aggregate type of photosensitizer) photosensitive peptide nanofibrillar network with greatly enhanced photothermal and photodynamic properties. This strategy of "multiple daily low-intensity laser radiation after each intravenous injection of significantly low-dose of nanomaterials" demonstrated effective elimination of 4T1 orthotopic syngeneic breast cancer in mice. The technology for nanomaterial modulation based on living cell surface receptors, in this case tumor-associated α3β1 integrin, has great potential for clinical translation and is expected to improve the therapeutic efficacy against many cancers.
Related Papers
- → Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy(2015)923 cited
- → Fluorous photosensitizers enhance photodynamic therapy with perfluorocarbon nanoemulsions(2017)75 cited
- → Fluorous photosensitizers enhance photodynamic therapy with perfluorocarbon nanoemulsions(2017)4 cited
- → Research advances in action mechanisms of photodynamic therapy and photosensitizer(2016)
- → Fluorous photosensitizers enhance photodynamic therapy with perfluorocarbon nanoemulsions(2017)